Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer

NCT00062101 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

NIH

Sponsor class

Conditions

Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: erlotinib hydrochloride
DRUG: celecoxib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)